Document Detail


Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva.
MedLine Citation:
PMID:  22750258     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To evaluate the efficacy and toxicity of erlotinib in the management of squamous cell carcinoma (SCC) of the vulva.
METHODS: Patients with vulvar lesions amenable to surgery or chemoradiation (cohort 1) or those with metastatic measurable disease (cohort 2) received erlotinib 150 mg daily. Patients were monitored for toxicity. Responses were determined by digital photography or RECIST 1.1. Cohort 1 underwent pre and post treatment biopsies. EGFR immunohistochemistry (IHC), fluorescence in-situ hybridization (FISH), and mutational analysis were performed.
RESULTS: 41 patients were enrolled: 17 in cohort 1 and 24 in cohort 2. Notable grade 3 or 4 toxicities included allergic reaction (1), diarrhea/electrolyte abnormalities (3), ischemic colitis (1), and renal failure (3) and electrolyte abnormalities (n=2). Mean number of cycles for cohort 2 was 3.3. Overall clinical benefit rate was 67.5% with 11 (27.5%) partial responses (PR), 16 (40.0%) stable disease (SD), and 7 (17.5%) progressive disease. Responses were of short duration. All pre and post treatment biopsies exhibited 2-3+ EGFR staining. 5 of 14 patients (35%) were found to have EGFR amplification (n=3) or high polysomy/trisomy (n=2). These five patients had either a PR (n=3) or SD (n=2). Gain of function mutations were not been identified.
CONCLUSIONS: This is the first reported controlled trial evaluating erlotinib for the management of vulvar carcinoma. Toxicities were acceptable given the lack of treatment options for these patients. Given the observed clinical benefits erlotinib may represent one of the most active agents available to treat vulvar SCC.
Authors:
N S Horowitz; A B Olawaiye; D R Borger; W B Growdon; C N Krasner; U A Matulonis; J F Liu; J Lee; L Brard; D S Dizon
Related Documents :
23029628 - Salvage therapy for refractory aids-related primary central nervous system lymphoma.
22290218 - Hcc: current surgical treatment concepts.
22805628 - Association between timing of epinephrine administration and intact neurologic survival...
22295128 - Prognostic factors for metastatic colorectal cancer patients undergoing irinotecan-base...
12162768 - Nodal metastasis in major salivary gland cancer: predictive factors and effects on surv...
11744828 - High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory...
Publication Detail:
Type:  Clinical Trial, Phase II; Journal Article; Multicenter Study     Date:  2012-06-26
Journal Detail:
Title:  Gynecologic oncology     Volume:  127     ISSN:  1095-6859     ISO Abbreviation:  Gynecol. Oncol.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-09-03     Completed Date:  2013-02-06     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  0365304     Medline TA:  Gynecol Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  141-6     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Affiliation:
Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA. nhorowitz@partners.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Carcinoma, Squamous Cell / drug therapy*,  pathology
Cohort Studies
Female
Humans
Middle Aged
Protein Kinase Inhibitors / adverse effects,  therapeutic use*
Quinazolines / adverse effects,  therapeutic use*
Vulvar Neoplasms / drug therapy*,  pathology
Chemical
Reg. No./Substance:
0/Protein Kinase Inhibitors; 0/Quinazolines; J4T82NDH7E/erlotinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A novel role for FOXA2 and SHH in organizing midbrain signaling centers.
Next Document:  Efficacy of lafutidine, a histamine H2-receptor antagonist, for taxane-induced peripheral neuropathy...